Transcatheter edge-to-edge repair utilizing the MitraClip system is an interventional cardiac procedure that restores functional mechanical competence to a leaking mitral valve. The primary treatment objective is to eliminate or significantly decrease severe mitral regurgitation (MR)—a condition where blood flows backward from the left ventricle into the left atrium during ventricular contraction. By mechanically grasping and joining the central portions of the mitral valve leaflets, the device replicates the surgical Alfieri edge-to-edge repair technique without requiring open-heart surgery, sternotomy, or cardiopulmonary bypass. The procedure falls within the medical domain of interventional cardiology and structural heart disease management.

Transcatheter edge-to-edge repair is performed under general anesthesia with continuous transesophageal echocardiography (TEE) and fluoroscopy guidance. Access is established through the right femoral vein using a large-bore introductory sheath. A catheter is advanced into the right atrium, and a precise transseptal puncture is performed under TEE to cross into the left atrium. A steerable guide catheter (SGC) is then positioned within the left atrium. The Clip Delivery System (CDS) carrying the folded clip is advanced through the guide catheter and positioned directly above the mitral valve origin of regurgitation. The device is oriented perpendicular to the line of coaptation and advanced into the left ventricle below the leaflets. Upon pullback, the clip arms are opened to catch both the anterior and posterior leaflets simultaneously. Leaflet grasping is confirmed on echocardiography, ensuring adequate tissue bridge, reduction of mitral regurgitation to Grade 2+ or lower, and maintenance of an acceptable mean transvalvular gradient (typically under 5 mmHg). Once stability and efficacy are confirmed, the clip is deployed and detached from the delivery system. If residual significant regurgitation persists and anatomical space permits, a second or third clip may be deployed using the same protocol. Finally, the delivery system is withdrawn, and the femoral vein puncture is closed using percutaneous suture-based closure devices or manual compression.

Evidence from landmark clinical trials demonstrates that transcatheter edge-to-edge repair significantly improves functional status, quality of life, and survival in appropriately selected patients. In secondary mitral regurgitation, trial data show a significant reduction in annual heart failure hospitalizations and lower 2-year all-cause mortality compared to medical therapy alone. Clinical outcomes include reduced left ventricular volume (favorable cardiac remodeling), improved 6-minute walk distance, and a shift in New York Heart Association (NYHA) functional class from symptomatic Class III/IV to Class I/II in the majority of treated individuals. Furthermore, as a percutaneous approach, it eliminates the morbidity associated with median sternotomy and cardiopulmonary bypass, resulting in shorter hospital stays and faster physical recovery.

Immediate recovery involves strict bed rest for 4 to 6 hours after vascular sheath removal to ensure hemostasis at the femoral access site. Most patients are ambulatory on post-procedure day one and are discharged within 24 to 72 hours. Initial physical restrictions include avoiding heavy lifting (greater than 10 pounds) and strenuous exertion for 1 to 2 weeks to allow the femoral vein access site to heal. Dual or single antiplatelet therapy is typically prescribed for 1 to 6 months based on underlying clinical indications. Patients experience gradual functional improvement over 30 to 90 days as the heart adapts to reduced regurgitant volume. Clinical follow-up includes an echocardiogram at 30 days to evaluate clip stability, residual regurgitation, and mean transvalvular gradient.

This procedure is designed to treat moderate-to-severe (3+) or severe (4+) mitral regurgitation. This encompasses two major clinical phenotypes: primary (degenerative) mitral regurgitation, where structural defects of the valve apparatus (such as leaflet prolapse, flail leaflet, or chordal rupture) cause improper closure; and secondary (functional) mitral regurgitation, where the valve leaflets are structurally normal but fail to coapt properly due to left ventricular dilation, ischemic cardiomyopathy, or non-ischemic dilated cardiomyopathy. The treatment is specifically tailored for individuals who remain severely symptomatic despite full guideline-directed medical therapy or who face excessive surgical risk for conventional open repair or replacement.

Pre-procedural preparation requires a detailed diagnostic evaluation. Patients undergo a baseline transthoracic echocardiogram (TTE) followed by a specialized transesophageal echocardiogram (TEE) to measure precise anatomical parameters, including leaflet length, coaptation depth, coaptation length, and flail gap. A multi-slice computed tomography (CT) scan of the pelvis and abdomen may be obtained to map femoral access pathways if peripheral artery disease or anatomical variants are suspected. Routine blood work includes complete blood count, renal panel, coagulation parameters, and cardiac biomarkers. Guideline-directed medical therapy for heart failure is optimized for at least several weeks prior to consideration of intervention. Antiplatelet or anticoagulant regimens are managed according to cardiac electrophysiology and interventional guidelines, with oral anticoagulants typically held briefly prior to the procedure. Patients must fast for 8 hours before general anesthesia.

While percutaneous transcatheter repair carries a lower risk profile than open-heart surgery, procedural and post-procedural complications can occur. Minor or common side effects include localized hematoma or bruising at the femoral access site, transient atrial arrhythmias (such as atrial fibrillation), and mild post-procedural groin pain. Less common complications include vascular access site bleeding requiring transfusion, pseudoaneurysm formation, clip detachment or single leaflet device attachment (SLDA) occurring in 1% to 3% of cases, and moderate elevation in transmitral mean pressure gradient. Severe but rare complications (occurring in under 1% to 2% of patients) include cardiac perforation leading to pericardial tamponade, ischemic stroke or systemic embolism, severe acute mitral stenosis, infectious endocarditis, emergency conversion to open surgical repair, and procedure-related mortality.

The clinical trajectory for transcatheter edge-to-edge repair begins with an extensive pre-procedural assessment by a multidisciplinary Heart Team, including transesophageal echocardiography to confirm anatomical suitability and risk stratification. On the day of the intervention, the procedure is performed under general anesthesia in a catheterization laboratory using continuous echocardiographic and fluoroscopic guidance. Access is gained via the femoral vein, followed by a controlled transseptal puncture to reach the left atrium. The clip is navigated, aligned, and deployed across the leaking valve leaflets. Following clip placement, the patient spends 12 to 24 hours in a monitored cardiac unit before transitioning to a general ward. Most individuals are discharged within 1 to 3 days, resuming mild activities within a week and undergoing serial echocardiographic follow-up at 30 days, 6 months, and annually thereafter.